Radiation meets immunotherapy-a perfect match in the era of combination therapy?

International Journal of Radiation Biology

Volumn 91, Issue 4, 2015, Pages 299-305

  Soukup, Klara ^a,b   Wang, Xinhui ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

Cancer; Combination therapy; Immunotherapy; Radiation; Radiotherapy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB;

B CELL LYMPHOMA; BRACHYTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMMUNOMODULATION; KIDNEY CARCINOMA; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; REVIEW; SOLID TUMOR; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS; TUMOR ESCAPE;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; NEOPLASMS; TUMOR ESCAPE;

EID: 84926059486     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553002.2014.995383     Document Type: Review

References (86)

1. Ahmed MM, Hodge JW, Guha C, Bernhard EJ, Vikram B, Coleman CN. 2013. Harnessing the potential of radiation-induced immune modulation for cancer therapy. Cancerimmunol Res 1: 280-284.
2. Akins EJ, Dubey P. 2008. Noninvasive imaging of cell-mediated therapy for treatment of cancer. J Nucl Med 49: 180s-195s.
3. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryff el B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
4. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. 1999. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17 : 2105-2116.
5. Barker CA, Postow MA. 2014. Combinations of radiation therapy and immunotherapy for melanoma: A review of clinical outcomes.int J Radiat Oncol Biol Phys 88: 986-997.
6. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, Lee NY, Wolchok JD. 2013. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancerimmunol Res 1 : 92-98.
7. Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, Kalnicki S, Hodge JW, Guha C. 2014. Radiationinduced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 29 : 153-161.
8. Brahmer JR, Pardoll DM. 2013.immune checkpoint inhibitors: Making immunotherapy a reality for the treatment of lung cancer. Cancerimmunol Res 1: 85-91.
9. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM. 2012. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 : 2455-2465.
10. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapniri, Tibshirani RJ, Levy R. 2010.in situ vaccination with a TLR9 agonist induces systemic lymphoma regression: A phasei/II study. J Clin Oncol 28 : 4324-4332.
11. Burnette B, Fu YX, Weichselbaum RR. 2012. The confl uence of radiotherapy and immunotherapy. Front Oncol 2: 143.
12. Cameron RB, Spiess PJ, Rosenberg SA. 1990. Synergistic antitumor activity of tumor-infi ltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action. J Exp Med 171 : 249-263.
13. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. 2004. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 64: 4328-4337.
14. Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW. 2003.irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. Jimmunol 170: 6338-6347.
15. Chakraborty M, Gelbard A, Carrasquillo JA, Yu S, Mamede M, Paik CH, Camphausen K, Schlom J, Hodge JW. 2008a. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor eff ects. Cancerimmunolimmunother 57 : 1173-1183.
16. Chakraborty M, Wansley EK, Carrasquillo JA, Yu S, Paik CH, Camphausen K, Becker MD, Goeckeler WF, Schlom J, Hodge JW. 2008b. The use of chelated radionuclide (samarium-153- ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing. Clin Cancer Res 14: 4241-4249.
17. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, Hsieh SL. 2005. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. Jimmunother 28 : 129-135.
18. Corso CD, Ali AN, Diaz R. 2011. Radiation-induced tumor neoantigens:imaging and therapeutic implications. Am J Cancer Res 1: 390-412.
19. Couzin-Frankel J. 2013. Breakthrough of the year 2013. Cancer immunotherapy. Science 342: 1432-1433.
20. Demaria S, Bhardwaj N, McBride WH, Formenti SC. 2005a. Combining radiotherapy and immunotherapy: A revived partnership. Int J Radiat Oncol Biol Phys 63: 655-666.
21. Demaria S, Vanpouille-Box C, Formenti SC, Adams S. 2013. Th e TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer. Oncoimmunology 2 : e25997.
22. Demaria S, Pilones KA, Vanpouille-Box C, Golden EB, Formenti SC. 2014. The optimal partnership of radiation and immunotherapy: From preclinical studies to clinical translation. Radiat Res 182 : 170-181.
23. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. 2004.ionizing radiation inhibition of distant untreated tumors (abscopal eff ect) is immune mediated.int J Radiat Oncol Biol Phys 58: 862-870.
24. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, Formenti SC. 2005b.immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11 : 728-734.
25. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. 2014.irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clininvest 124 : 687-695.
26. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal eff ect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15 : 5379-5388.
27. Diamond J, Vanpouille-Box C, Barcellos-Hoff MH, Formenti SC, Demaria S. 2013. The abscopal eff ect of local radiotherapy is induced by TGF® blockade. Jimmunother Cancer 1: P115.
28. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. 2011. Features associated with survival in metastatic melanoma patients treated with patient-specifi c dendritic cell vaccines. Cancer Biother Radiopharm 26: 407-415.
29. Dohnal AM, Witt V, Hugel H, Holter W, Gadner H, Felzmann T. 2007. Phasei study of tumor Ag-loadediL-12 secreting semi-mature DC for the treatment of pediatric cancer. Cytotherapy 9: 755-770.
30. Draghiciu O, Walczak M, Hoogeboom BN, Franken KL, Melief KJ, Nijman HW, Daemen T. 2014. Th erapeutic immunization and local low-dose tumor irradiation, a reinforcing combination.int J Cancer 134 : 859-872.
31. Finkelstein SE,iclozan C, Bui MM, Cotter MJ, Ramakrishnan R, Ahmed J, Noyes DR, Cheong D, Gonzalez RJ, Heysek RV, Berman C, Lenox BC, Janssen W, Zager JS, Sondak VK, Letson GD, Antonia SJ, Gabrilovich DI. 2012. Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neoadjuvant treatment of high-risk soft tissue sarcoma patients.int J Radiat Oncol Biol Phys 82: 924-932.
32. Fishman M. 2014. Challenges facing the development of cancer vaccines. Methods Mol Biol 1139 : 543-553.
33. Formenti SC, Demaria S. 2009. Systemic eff ects of local radiotherapy. Lancet Oncol 10 : 718-726.
34. Formenti SC, Demaria S. 2013. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancerinst 105: 256-265.
35. Frey B, Rubner Y, Kulzer L, Werthmoller N, Weiss EM, Fietkau R, Gaipl US. 2014. Antitumor immune responses induced by ionizing irradiation and further immune stimulation. Cancerimmunol Immunother 63 : 29-36.
36. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. 2014. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 5: 403-416.
37. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. 2002. Combination of T-cell therapy and trigger of infl ammation induces remodeling of the vasculature and tumor eradication. Cancer Res 62 : 1462-1470.
38. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. 2004. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 64: 7985-7994.
39. Grivennikov SI, Greten FR, Karin M. 2010.immunity, infl ammation, and cancer. Cell 140: 883-899.
40. Gulley JL, Madan RA, Tsang KY, Arlen PM, Camphausen K, Mohebtash M, Kamrava M, Schlom J, Citrin D. 2011. A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver. Expert Opin Biol Th er 11 : 1409-1418.
41. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang KY, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, S chlom J, Dahut W. 2005. Combining a recombinant cancer vaccine with standard defi nitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 11 : 3353-3362.
42. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Pruschy M, Knuth A, van den Broek M. 2012. Radiotherapy promotes tumor-specifi c eff ector CD8 - T cells via dendritic cell activation. Jimmunol 189: 558-566.
43. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Keff ord R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 : 134-144.
44. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: The next generation. Cell 144 : 646-674.
45. Heery C, Madan R, Bilusic M, Kim J, Singh N, Rauckhorst M, Chen C, Dahut W, Stadler W, Dipaola R, Stein M, Hodge J, Schlom J. 2012. Interim analysis of a phaseiI randomized clinical trial of samarium- 153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration-resistant prostate cancer after docetaxel. J Clin Oncol 30 : Abstract 2526.
46. Hodge JW, Sharp HJ, Gameiro SR. 2012. Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation. Cancer Biother Radiopharm 27: 12-22.
47. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. 2013. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73: 2943-2948.
48. Ina Y, Sakai K. 2005. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: Analysis of immune cell populations and surface molecules.int J Radiat Biol 81 : 721-729.
49. Kalbasi A, June CH, Haas N, Vapiwala N. 2013. Radiation and immunotherapy: A synergistic combination. J Clininvest 123 : 2756-2763.
50. Kelderman S, Schumacher TN, Haanen JB. 2014. Acquired and intrinsic resistance in cancer immunotherapy. Mol Oncol 8 : 1132-1139.
51. Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK. 2013. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. Oncoimmunology 2 : e25962.
52. Kim R, Emi M, Tanabe K. 2006. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Expimmunol 146 : 189-196.
53. Klug F, Prakash H, Huber PE, Seibel T, Bender N, Halama N, Pfi rschke C, Voss RH, Timke C, Umansky L, Klapproth K, Schakel K, Garbi N, Jager D, Weitz J, Schmitz-Winnenthal H, Hammerling GJ, Beckhove P. 2013. Low-dose irradiation programs macrophage diff erentiation to an iNOS( - )/M1 phenotype that orchestrates eff ective T cell immunotherapy. Cancer Cell 24: 589-602.
54. Kwilas AR, Donahue RN, Bernstein MB, Hodge JW. 2012.in the field: Exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol 2: 104.
55. Lechleider RJ, Arlen PM, Tsang KY, Steinberg SM, Yokokawa J, Cereda V, Camphausen K, Schlom J, Dahut WL, Gulley JL. 2008. Safety and immunologic response of a viral vaccine to prostatespecifi c antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res 14: 5284-5291.
56. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX. 2009. Th erapeutic eff ects of ablative radiation on local tumor require CD8 - T cells: Changing strategies for cancer treatment. Blood 114: 589-595.
57. Lim JY, Gerber SA, Murphy SP, Lord EM. 2014. Typei interferons induced by radiation therapy mediate recruitment and eff ector function of CD8( - ) T cells. Cancerimmunolimmunother 63 : 259-271.
58. Lipson EJ, Drake CG. 2011.ipilimumab: An anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res 17 : 6958-6962.
59. Liu Z, Li Z. 2014. Molecular imaging in tracking tumor-specifi c Cytotoxic T Lymphocytes (CTLs). Th eranostics 4 : 990-1001.
60. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. 2005. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specifi c eff ector cells that traffi c to the tumor. Jimmunol 174 : 7516-7523.
61. Matsumura S, Demaria S. 2010. Up-regulation of the pro-infl ammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 173: 418-425.
62. McBride WH, Chiang CS, Olson JL, Wang CC, Hong JH, Pajonk F, Dougherty GJ,iwamoto KS, Pervan M, Liao YP. 2004. A sense of danger from radiation. Radiat Res 162: 1-19.
63. McDermott DF. 2007. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 13 : 716s-720s.
64. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, Metivier D, Larochette N, van Endert P, Ciccosanti F, Piacentini M, Zitvogel L, Kroemer G. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61.
65. Pardoll DM. 2012. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264.
66. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, Sedrak C, Jungbluth AA, Chua R, Yang AS, Roman RA, Rosner S, Benson B, Allison JP, Lesokhin AM, Gnjatic S, Wolchok JD. 2012.immunologic correlates of the abscopal eff ect in a patient with melanoma. N Engl J Med 366 : 925-931.
67. Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. 2014. Tumor immunology and cancer immunotherapy: Summary of the 2013 SITC primer. Jimmunother Cancer 2 : 14.
68. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. 2006. Radiation modulates the peptide repertoire, enhances MHC classi expression, and induces successful antitumor immunotherapy. J Exp Med 203: 1259-1271.
69. Roses RE, Datta J, Czerniecki BJ. 2014. Radiation as immunomodulator: Implications for dendritic cell-based immunotherapy. Radiat Res 182: 211-218.
70. Safwat A, Aggerholm N, Roitti, Overgaard J, Hokland M. 2003. Low-dose total body irradiation augments the therapeutic eff ect of interleukin-2 in a mouse model for metastatic malignant melanoma. J Exp Th er Oncol 3 : 161-168.
71. Safwat A, Aggerholm N, Roitti, Overgaard J, Hokland M. 2004. Tumour burden and interleukin-2 dose aff ect the interaction between lowdose total body irradiation and interleukin 2. Eur J Cancer 40 : 1412-1417.
72. Schaue D, Ratikan JA,iwamoto KS, McBride WH. 2012. Maximizing tumor immunity with fractionated radiation.int J Radiat Oncol Biol Phys 83: 1306-1310.
73. Schreiber RD, Old LJ, Smyth MJ. 2011. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331 : 1565-1570.
74. Schwartz RN, Stover L, Dutcher J. 2002. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16: 11-20.
75. Seung SK, Curti BD, Crittenden M, Urba W. 2012a. Radiation and immunotherapy: Renewed allies in the war on cancer. Oncoimmunology 1 : 1645-1647.
76. Seung SK, Curti BD, Crittenden M, Walker E, Coff ey T, Siebert JC, Miller W, Payne R, Glenn L, Bageac A, Urba WJ. 2012b. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci Transl Med 4 : 137ra74.
77. Shen RN, Hornback NB, Shidnia H, Lu L, Montebello JF, Brahmi Z. 1988. A comparison of lung metastases and natural killer cell activity in daily fractions and weekly fractions of radiation therapy on murine B16a melanoma. Radiat Res 114: 354-360.
78. Shigematsu A, Adachi Y, Koike-Kiriyama N, Suzuki Y,iwasaki M, Koike Y, Nakano K, Mukaide H,imamura M,ikehara S. 2007. Eff ects of low-dose irradiation on enhancement of immunity by dendritic cells. J Radiat Res 48: 51-55.
79. Siegel JP, Puri RK. 1991.interleukin-2 toxicity. J Clin Oncol 9 : 694-704.
80. Slovin S, Beer T, Higano CS, Tejwani S, Hamid O, Picus J, Harzstark A, Scher HI, Lan Z, Lowyi. 2009.initial phaseiI experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 27 : Abstract 5138.
81. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, Beer TM. 2013.ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: Results from an open-label, multicenter phasei/II study. Ann Oncol 24 : 1813-1821.
82. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 : 2443-2454.
83. Wattenberg MM, Fahim A, Ahmed MM, Hodge JW. 2014. Unlocking the combination: Potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res 182: 126-138.
84. Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, Snook AE. 2014. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.int J Radiat Oncol Biol Phys 88: 1188-1195.
85. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowyi,inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. 2013. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369: 122-133.
86. Youn H, Hong KJ. 2012.in vivo non invasive molecular imaging for immune cell tracking in small animals.immune Netw 12: 223-229.